Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Stephen Lam Chan"'
Autor:
Choong-kun Lee, Changhoon Yoo, Jung Yong Hong, Se Jun Park, Jin Won Kim, David Wai Meng Tai, Hyeyeong Kim, Krittiya Korphaisarn, Suebpong Tanasanvimon, San-Chi Chen, Ju Won Kim, Ilhwan Kim, Moonho Kim, Joan Choo, Sang-Bo Oh, Ching-Tso Chen, Woo Kyun Bae, Hongsik Kim, Seok Jae Huh, Chia-Jui Yen, Sejung Park, Dong Ki Lee, Landon Long Chan, Beodeul Kang, Minsu Kang, Raghav Sundar, Hye Jin Choi, Stephen Lam Chan, Hong Jae Chon, Myung-Ah Lee
Publikováno v:
Liver Cancer, Pp 1-15 (2024)
Introduction: Atezolizumab plus bevacizumab is a commonly used first-line regimen for advanced hepatocellular carcinoma (HCC) treatment owing to its superior outcomes compared to sorafenib. However, optimal subsequent treatment options for patients w
Externí odkaz:
https://doaj.org/article/48cd992dee674cbb8551afa29b350663
Autor:
Xiaoyu Liu, Man Liu, Haoran Wu, Wenshu Tang, Weiqin Yang, Thomas T.H. Chan, Lingyun Zhang, Shufen Chen, Zhewen Xiong, Jianxin Liang, Willis Wai-Yiu Si-Tou, Ting Shu, Jingqing Li, Jianquan Cao, Chengpeng Zhong, Hanyong Sun, Tsz Tung Kwong, Howard H.W. Leung, John Wong, Paul Bo-San Lai, Ka-Fai To, Tingxiu Xiang, Joseph Jao-Yiu Sung, Stephen Lam Chan, Jingying Zhou, Alfred Sze-Lok Cheng
Publikováno v:
JHEP Reports, Vol 6, Iss 7, Pp 101087- (2024)
Background & Aims: Recent studies demonstrated the importance of fibrosis in promoting an immunosuppressive liver microenvironment and thereby aggressive hepatocellular carcinoma (HCC) growth and resistance to immune checkpoint blockade (ICB), partic
Externí odkaz:
https://doaj.org/article/548a0fa4c9c849b8b8cb170ca38dbeaf
Publikováno v:
Journal of Liver Cancer, Vol 23, Iss 2, Pp 262-271 (2023)
Hepatocellular carcinoma (HCC) frequently presents as advanced stage with poor prognosis and high mortality. Systemic treatment is the treatment of choice for advanced disease. In 2007, the first multi-kinase inhibitor (MKI) sorafenib was approved an
Externí odkaz:
https://doaj.org/article/1c49ebdb3a6c4f39aed29a0a858c4aeb
Autor:
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan
Publikováno v:
Clinical and Molecular Hepatology, Vol 29, Iss 2, Pp 277-292 (2023)
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree o
Externí odkaz:
https://doaj.org/article/939b6e7180de46e9a686c87a0401fd8b
Publikováno v:
Current Oncology, Vol 29, Iss 8, Pp 5489-5507 (2022)
Hepatocellular carcinoma (HCC) has high mortality. The option of systemic therapy has increased significantly over the past five years. Sorafenib was the first multikinase inhibitor, introduced in 2007, as a treatment option for HCC, and it was the o
Externí odkaz:
https://doaj.org/article/9b6f1eb5348344eaad2d936072fea0d6
Autor:
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Publikováno v:
Liver Cancer (2023)
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall surviva
Externí odkaz:
https://doaj.org/article/cd768b0d783a455fbb086706dc35b886
Autor:
Chi Hin Wong, Ut Kei Lou, Frederic Khe-Cheong Fung, Joanna H. M. Tong, Chang-hua Zhang, Ka-Fai To, Stephen Lam Chan, Yangchao Chen
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-15 (2022)
Abstract Background Circular RNAs (circRNAs) play important roles in many biological processes. However, the detailed mechanism underlying the critical roles of circRNAs in cancer remains largely unexplored. We aim to explore the molecular mechanisms
Externí odkaz:
https://doaj.org/article/0809fdecbc0a4741a5ee9cfc386e59c8
Autor:
Khi Yung Fong, Joseph Jonathan Zhao, Rehena Sultana, Joycelyn Jie Xin Lee, Suat Ying Lee, Stephen Lam Chan, Thomas Yau, David Wai Meng Tai, Raghav Sundar, Chow Wei Too
Publikováno v:
Liver Cancer (2022)
Introduction: Sorafenib was historically the standard of care for advanced hepatocellular carcinoma (aHCC) until it was superseded by the combination of atezolizumab and bevacizumab. Thereafter, several novel first-line combination therapies have dem
Externí odkaz:
https://doaj.org/article/8acd990a891043b68eeb453237bb5c8a
Autor:
Stephen Lam Chan, Chanisa Chotipanich, Su Pin Choo, Su Wen Kwang, Frankie Mo, Akeanong Worakitsitisatorn, David Tai, Raghav Sundar, David Chee Eng Ng, Kelvin Siu Hoong Loke, Leung Li, Kelvin Kwok Chai Ng, Yong Wei Peng, Simon Chun-Ho Yu
Publikováno v:
Liver Cancer (2022)
Introduction: This investigator-initiated clinical trial aims to study the efficacy and safety of administering selective internal radiation therapy with resin yttrium-90 microspheres (SIRT) followed by standard chemotherapy in unresectable intrahepa
Externí odkaz:
https://doaj.org/article/dd1f3796cda14d48aad479d69662ad9e
Autor:
Thomas Yau, David Tai, Stephen Lam Chan, Yi-Hsiang Huang, Su Pin Choo, Chiun Hsu, Tan To Cheung, Shi-Ming Lin, Wei Peng Yong, Joycelyn Lee, Thomas Leung, Tracy Shum, Cynthia S. Y. Yeung, Anna Yin-Ping Tai, Ada Lai Yau Law, Ann-Lii Cheng, Li-Tzong Chen
Publikováno v:
Liver Cancer (2022)
Background: Asia has a high burden of hepatocellular carcinoma (HCC) due to the high rates of chronic hepatitis B infection, and accounts for 70% of HCC cases globally. In the past 20 years, the systemic treatment landscape of advanced HCC has evolve
Externí odkaz:
https://doaj.org/article/40f6cf6d91f4490ba3706de915130645